NL-OMON22782已完成不适用
FOsfomycin Randomised controlled trial for E.coli Complicated urinary tract infections as Alternative Stepdown Treatment
niversity Medical Center, Utrecht0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 240
研究概览
简要总结
Follows
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Hospitalised
- •Competent women (≥18 years), able to give informed consent
- •AF-UTI as presumptive diagnosis and primary reason for hospitalisation*
- •Adequate intravenous antibiotic therapy for ≥48 - ≤120 hours**
- •Candidate for safe iv to oral switch as judged by the attending physician
- •Urine (≥10^4 CFU/ml) OR blood culture: Escherichia coli , ciprofloxacin S AND fosfomycin S***
- •* Acute Febrile Urinary Tract Infections (AF-UTI) are UTI with at least one of the forthcoming systemic signs or symptoms: fever or low temperature (≥38.0 C ͦ or <36 C ͦ), rigors, delirium, hemodynamic instability as a result of sepsis requiring intravenous fluids, increase in CRP (≥30mg/L) or leucocytes (≥12*109/L) AND at least one of the following local symptoms: lower abdominal pain, low back pain, flank pain or costo-vertebral angle pain or tenderness on physical examination, any of the following symptoms of UTI (dysuria, urinary urgency, urinary frequency, suprapubic/pelvic discomfort, macroscopic hematuria, new urinary incontinence or worsening of pre-existing incontinence). Local symptoms are not required if urine and blood culture yield phenotypically identical E.coli and UTI is the presumed source of infection according to the treating physician. The local study investigator determines the presumptive diagnosis as the primary reason for hospitalization with consultation of the attending physician.
- •**Amoxicillin+/-clavulanic acid / 2nd or 3rd cephalosporin/ aminoglycoside/ carbapenem/ fluoroquinolones/ trimethoprim-sulfamethoxazole OR a combination AND in vitro susceptibility of the causative E.coli to at least one of the used agents
- •*** If a participating microbiological laboratory only processes urine cultures ≥ 105 CFU/ml, only these will be included. If an urine or blood culture results in another non-E.coli bacteria that requires antibiotic treatment, the patient should be excluded. A patient is not eligible if non-E.coli-type Enterobacteriaceae are present in urine culture (≥103 CFU/ml) or blood culture.
排除标准
- •Pregnant or nursing women
- •Glomerular filtration rate < 30 ml/min/1,73 m2 or renal replacement therapy
- •Concomitant systemic antibacterial treatment for another reason than AF-UTI including concomitant prophylactic antibacterial therapy #
- •Ascertained or presumptive hypersensitivity to the active compounds and/or any excipient of the products or to any quinole
- •Participation to any trial with an investigational product involved in the 30 days before the screening visit
- •Every other laboratory result, clinical condition, disease or treatment that, in investigator’s opinion, make the subject non suitable for the study
- •Specific comorbidity or diagnosis##
- •Contraindications/interactions for any of the active compounds or medication ###
- •Patients with inadequate understanding of the study risks or its requirements or unwilling to plan a follow-up visit
- •# If prophylactic antibiotic therapy for UTI could not be paused during study therapy, the patient should be excluded
研究者
相似试验
已完成
3 期
FOsfomycin Randomised controlled trial for E.coli Complicated urinary tract infections as Alternative Stepdown TreatmentComplicated urinary tract infectionascending urinary tract infection10004018NL-OMON47265niversitair Medisch Centrum Utrecht240
进行中（未招募）
1 期
Fosfomycin as stepdown treatment for ascending urinary tract infectionsAcute febrile urinary tract infectionMedDRA version: 20.0Level: LLTClassification code 10046574Term: Urinary tract infection NOSSystem Organ Class: 100000017512MedDRA version: 20.0Level: LLTClassification code 10046576Term: Urinary tract infection, site not specifiedSystem Organ Class: 100000017512EUCTR2016-004486-37-NLniversity Medical Centre Utrecht
已完成
2 期
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in ChildrenMalariaNCT01464138Jomaa Pharma GmbH52
招募中
3 期
A Trial of Fosfomycin vs Ciprofloxacin for Febrile NeutropeniaFebrile NeutropeniaNCT05311254Fundación para la Investigación Biosanitaria del Principado de Asturias156
已完成
不适用
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial InfectionBacterial InfectionNCT01173575Infectopharm Arzneimittel GmbH209